Has Anyone Died From Retatrutide? Trial Deaths and FDA Reports

Yes, people have died while taking retatrutide in clinical trials: across the 5 trials that published a death count, 13 people on retatrutide died, against 3 on placebo. Where the papers give a verdict on cause (TRANSCEND-T2D-1 and TRIUMPH-2), the investigators called every death unrelated to the drug. The retatrutide death reports in the news are a separate matter. CBS News reported on October 13, 2026 that the FDA had received 2 reports of women who died after using products sold as retatrutide outside any trial, and nobody has shown that those products caused the deaths. As of October 31, 2026, we found no regulator saying retatrutide caused anyone's death.

A trial death, an FDA report and a poison center call mean very different things, so each gets its own section. Retatrutide is still in Phase 3 trials and no approved version exists yet.

How many people died in the retatrutide trials?

Five published retatrutide trials give a death count. Across them, 13 people on retatrutide died, against 3 on placebo.

The Phase 2 counts come from the safety tables on ClinicalTrials.gov, where the obesity trial lists its death as "Drowning". The TRIUMPH-1 numbers come from Lilly Medical Information's adverse event table. TRANSCEND-T2D-1's paper says its 2 deaths were "unrelated to the study drug", and TRIUMPH-2's says all 7 of its deaths "were deemed to be unrelated to the study intervention by the investigator."

Then there's the gap. Lilly's per-trial figures show 7,720 people randomized across the six Phase 3 trials that have reported, and death counts are public for 4,028 of them, in TRANSCEND-T2D-1, TRIUMPH-1 and TRIUMPH-2 (our math). For the other 3,692, in TRIUMPH-3, TRIUMPH-4 and TRANSCEND-T2D-2, Lilly's releases give no number. Our Phase 3 results page covers each trial.

Were the trial deaths caused by retatrutide?

The TRANSCEND-T2D-1 and TRIUMPH-2 investigators said no for every death. The TRIUMPH-1 table gives causes instead of a verdict: the placebo deaths were a motor vehicle accident and a gunshot wound; the 9 mg deaths were a motor vehicle accident and 2 sudden deaths, one non-cardiovascular and one of undetermined cause; and the 12 mg death was a cardiovascular death in a person with known heart failure who had been off the study drug for 189 days. The NEJM paper may state relatedness, but we couldn't open it.

Two things in the numbers fit "not caused by the drug". First, the raw counts look more lopsided than they are, because these trials put about 3 people on retatrutide for every 1 on placebo. In TRIUMPH-1 and TRIUMPH-2 together, 10 of 2,612 on retatrutide died (0.4%, about 4 in 1,000), against 3 of 875 on placebo (0.3%, about 3 in 1,000; our math). With so few deaths, one more or fewer moves those rates a lot.

Second, the deaths don't climb with dose. TRIUMPH-1 had 0 on 4 mg, 3 on 9 mg and 1 on 12 mg; TRIUMPH-2 had 2, 3 and 1. Both deaths in TRANSCEND-T2D-1 were on 4 mg, the lowest dose. Across the three Phase 3 trials with counts, the 12 mg groups had 2 deaths among 1,005 people (our sum).

Our read: the counts show no pattern by dose and no clear excess over placebo, but they cover about half of the Phase 3 participants (4,028 of 7,720), so the question isn't closed.

Tirzepatide, Lilly's approved two-hormone drug, has a label warning that mentions deaths. The Zepbound label says acute pancreatitis, "including fatal and non-fatal hemorrhagic or necrotizing pancreatitis," has been seen in people on GLP-1 drugs or Zepbound. That's tirzepatide data, not retatrutide; see pancreatitis and gallbladder for the retatrutide numbers and rare side effects for serious events that didn't end in death.

Retatrutide death reports sent to the FDA

CBS News got 2 death reports from the FDA through a records request and described them on October 13, 2026, saying it couldn't verify them.

• The first came from a health care professional, who told the FDA that a 41-year-old woman with obesity went into cardiac arrest in July 2026. The report lists retatrutide as a "suspect product" that she got "from an unreliable source". CBS reported that she had also been drinking kava.
• The second reached the FDA in September 2026. It says a 49-year-old woman had severe dehydration, malnutrition and cardiac arrest after a licensed nurse "convinced" her to buy retatrutide from an online peptide vendor.

The FDA declined to tell CBS whether it had verified either report. Its statement said: "We review adverse event reports, gathering additional information when needed." Lilly told CBS that both women "were taking black-market retatrutide." According to CBS, neither death was linked to a clinical trial.

CBS was careful about what the reports show, writing that they "don't prove that the drugs caused or contributed to patient deaths." The FDA says the same about its own database. Its public data service, openFDA, warns that "a causal relationship cannot be established between product and reactions listed in a report" and that "FDA does not receive reports for every adverse event or medication error that occurs with a product."

What the public FAERS data shows

We pulled every openFDA report naming retatrutide on October 31, 2026. The feed was last updated July 30, 2026, and its newest retatrutide report was received June 27, 2026, so the July and September death reports aren't in it yet. openFDA warns that its data "may lag by 3 months or more."

Most are self-reports, and 29 of the 44 arrived in the first half of 2026 alone. Nobody knows how many people use products sold as retatrutide, so a report total can't be turned into a risk.

Poison center calls are rising, and they aren't death counts

CBS also reported, citing America's Poison Centers, 249 retatrutide exposures in the first 3 months of 2026, 460 in the next 3, and 862 in the 3 months ending in September. That's about 3.5 times as many in the third quarter as in the first (our math). CBS added that a steady rise is "common for a newly monitored drug", since the group only began tracking retatrutide late in 2025.

CBS didn't say how many of these cases were serious, and it reported no deaths among them. We couldn't find the counts on the America's Poison Centers site, so treat them as CBS's figures for now. If you think someone has injected too much or the wrong thing, the group's Poison Help line in the US is 1-800-222-1222.

Why the gray market is where the danger shows up

Lilly's October 2026 FAQ says retatrutide "has not been reviewed or approved by the FDA or any regulatory agency in the world, and no one can legally sell it for human use." Both FDA death reports, and every regulator case below, involve products that didn't come from Lilly.

The wrong drug in the vial

Australia's TGA tested an unmarked vial sold as retatrutide after a person had uncontrollable vomiting, a torn oesophagus and hospital treatment; its alert was published September 14, 2026. The lab found no retatrutide in the vial. It found semaglutide, the drug in Ozempic and Wegovy, at about 8 times the level in approved semaglutide products. Lilly's counterfeit page says Florida federal prosecutors have charged a seller whose "retatrutide" tested as a different active ingredient.

Contamination

Victoria's Chief Health Officer reported 6 cases of acute liver injury since January 2026 in people who used unapproved products labeled Retatrutide, Reta, R-10 or R-20, and said a contaminant may be to blame. The alert, issued June 19, 2026, was still active on October 31. Lilly's FAQ lists the general risks: unknown ingredients, contaminants and impurities, too much or too little active ingredient, or the wrong one.

Dosing errors

Products sold online come in vials that buyers measure out themselves, so a slip in the math changes the dose. The FDA has received multiple reports of adverse events, some needing hospital care, tied to dosing errors with compounded semaglutide, where patients measured the wrong amount or a health professional miscalculated. That's semaglutide, not retatrutide. In the openFDA data above, 6 of the 44 retatrutide reports mention an overdose or a dosing error.

If you're comparing retatrutide for sale online, none of it is Lilly's product, and a label or a seller's purity report doesn't tell you what's in the vial in your hand; the TGA's vial held no retatrutide at all. Our testing page explains what a batch-specific lab report can and can't confirm, and safety alerts tracks regulator warnings as they're issued.

Warning signs that need emergency care

Those are the NHS's emergency signs for palpitations and dehydration, plus the allergic reaction signs in the Zepbound medication guide. Both FDA death reports described cardiac arrest.

Get help the same day for:

• Severe stomach pain that won't go away, with or without vomiting, sometimes felt through to the back. The Zepbound label gives this as the sign of pancreatitis (class evidence).
• Dehydration that isn't easing: dark yellow pee, peeing less than normal, or dizziness on standing that doesn't go away, which the NHS says needs an urgent appointment. The Zepbound label also tells patients to report nausea, vomiting or diarrhea that keeps going.
• Yellow skin or eyes, dark urine, itchy skin or bruising easily, the signs in Victoria's liver injury alert.
• Shakiness, sweating, confusion or a fast heartbeat if you also take insulin or a sulfonylurea, since the Zepbound guide says those drugs raise the risk of low blood sugar.

Tell whoever treats you what you injected, how much, and where it came from, and bring the vial. Victoria's alert asks doctors to record those details and keep a sample or photos. In the US you can report a bad reaction or a suspect product to the FDA through MedWatch, and Lilly asks people to report illegal retatrutide products to the Lilly Answers Center at 1-800-LillyRx.

What nobody can answer yet

The biggest unknown is the death count for the 3,692 Phase 3 participants above. As of October 31, 2026, no Phase 3 trial has results posted on ClinicalTrials.gov; only the two Phase 2 trials do. The long answer will come from TRIUMPH-Outcomes, an event-driven trial of about 10,000 adults with overweight or obesity plus heart or kidney disease that tracks major cardiovascular and kidney outcomes; its primary completion is estimated for February 2029.

Outside trials, the FOIA documents behind the CBS story aren't public, and the FDA hasn't said whether it has followed up. In July 2026 The BMJ ran a fact check headlined "Has a man died after taking the unapproved weight loss jab?"; we could open only its listing, not the article, so we can't tell you what it found. For who shouldn't take retatrutide at all and what to monitor if you're in a trial, see is retatrutide safe.